Loc: hiv vaccine trials network

  • Description
  • Details
  • Subprojects
  • History
  • Publications
  • Patents
  • Trials
Project Title: Loc: hiv vaccine trials network
Project Number: 5UM1AI068614-11
Project web address: Follow on NIH
 
Project Description:
This proposal describes the organization of a comprehensive, multidisciplinary international HIV Vaccine Trials Network (HVTN). Components of the HVTN include a Leadership Coordinating and Operations Center (L. Corey, Contact PI; S. Hammer and G. Gray, PI's); a Statistical and Data Management Center (P. Gilbert, PI) and a Network Laboratory Program (M. J. McElrath, PI). The HVTN's mission is to provide an objective and transparent platform to evaluate candidate HIV vaccines for the prevention of HIV infection in adult and adolescent populations globally. To achieve this, the HVTN will perform safety, immunogenicity, and efficacy trials of candidate HIV vaccines and adjuvants; conduct head-to-head comparisons of candidate vaccines; develop laboratory and statistical approaches to define potential correlates of protection; design trials to estimate the effects of vaccines tha reduce HIV acquisition and reduction in set point viremia transmission; conduct trials of candidate vaccines in special populations, such as adolescents and intravenous drug users; develop standardized risk reduction counseling methods; and collaborate with other NIH networks, federal agencies and non-governmental research organizations to advance the highest quality HIV vaccine research with optimal efficiency and cost effectiveness.
 
Project Terms:
adjuvant adolescent adult aids prevention alcohol or other drugs use anti-retroviral agents antibodies antigens basic science behavioral sciences bioinformatics biological biometry characteristics clinical sciences clinical trials clinical trials design clinical trials network communities computational biology cost effectiveness counseling data management design detection development disease progression economics efficacy evaluation efficacy testing efficacy trial epidemic ethics evolution gender genes genetic genotype gray unit of radiation dose head-to-head comparison high throughput screening hiv hiv infections hiv vaccine hiv vaccine trials network hiv-1 human immune immune response immunity immunogenicity immunologic markers immunologics improved incidence infant infection infection prevention innate immune response insight international intravenous drug user laboratories leadership measurement methods mission modality monitor mucosal immune responses multidisciplinary named group nonhuman primate novel novel vaccines operation pandemic disease persons phase phase iii clinical trials phenotype politics population pregnant women prevent prevention prevention strategy process programs prototype reagent recruitment activity regimen research research personnel resources risk risk reduction route safety schedule signal transduction site standardization system t cell response transmission process trial design united states national institutes of health vaccination vaccine candidate vaccine development vaccine research vaccine trial vaccines vector viral load result viremia woman work
Project Title: Loc: hiv vaccine trials network
Project Number: 5UM1AI068614-11
Project web address: Follow on NIH
Organization: Fred Hutchinson Cancer Research Center, United States, Washington, SEATTLE
Principal Investigators (PI): Corey Lawrence, US
Gray Glenda E, US
Hammer Scott M, US
 
Project Categories:
Natural Sciences > Aging Diseases and Pathology > Immune system disorders and inflammation
 
Other Information:
Fiscal Year: 2006
Project Start Date: 29 June 2006
Project End Date: 30 November 2020
Project program: Research Project with Complex Structure Cooperative Agreement
 
Project Funding Information:
Funding Mechanism: Non-SBIR/STTR RPGs
Year Funding Organization Total Funding, $
2017 NIH - National Institute Of Allergy And Infectious Diseases $50,375,222
Project Title: Loc: hiv vaccine trials network
Project Number: 5UM1AI068614-11
Project web address: Follow on NIH
 
Title FY Funding
There are no results for this project in database.
Project Title: Loc: hiv vaccine trials network
Project Number: 5UM1AI068614-11
Project web address: Follow on NIH
 
Title Journal Year Country Rel
Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. Stat Commun Infect Dis 2017 united states
Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults. MAbs 2017 united states
The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United States. Vaccines (Basel) 2017 switzerland
Vaccination establishes clonal relatives of germinal center T cells in the blood of humans. J Exp Med 2017 united states
Pre-existing neutralizing antibody mitigates B cell dysregulation and enhances the Env-specific antibody response in SHIV-infected rhesus macaques. PLoS One 2017 united states
Ten Years HIV Free: An Interview with "The Berlin Patient," Timothy Ray Brown. Pathog Immun 2017 united states
SieveSifter: a web-based tool for visualizing the sieve analyses of HIV-1 vaccine efficacy trials. Bioinformatics 2017 england
Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults. PLoS One 2017 united states
Causal analysis of ordinal treatments and binary outcomes under truncation by death. J R Stat Soc Series B Stat Methodol 2017 england
Preventing acquisition of HIV is the only path to an AIDS-free generation. Proc Natl Acad Sci U S A 2017 united states
Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials. Vaccine 2017 netherlands
Broadly neutralizing antibodies to prevent HIV-1. Science 2017 united states
Using Digital Technologies in Clinical HIV Research: Real-World Applications and Considerations for Future Work. J Med Internet Res 2017 canada
Exploring evidence for behavioral risk compensation among participants in an HIV vaccine clinical trial. Vaccine 2017 netherlands
Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial. J Infect Dis 2017 united states
DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA. Clin Vaccine Immunol 2017 united states
Barriers and facilitators of HIV vaccine and prevention study participation among Young Black MSM and transwomen in New York City. PLoS One 2017 united states
Hope for HIV control in southern Africa: The continued quest for a vaccine. PLoS Med 2017 united states
The Case for Adolescent HIV Vaccination in South Africa: A Cost-Effectiveness Analysis. Medicine (Baltimore) 2016 united states
Impact of pre-adapted HIV transmission. Nat Med 2016 united states
? Light Chain Bias Associated With Enhanced Binding and Function of Anti-HIV Env Glycoprotein Antibodies. J Infect Dis 2016 united states
In men at risk of HIV infection, IgM, IgG1, IgG3, and IgA reach the human foreskin epidermis. Mucosal Immunol 2016 united states
Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants. PLoS One 2016 united states
Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy. PLoS One 2016 united states
Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap. Clin Vaccine Immunol 2016 united states
Transient Peripheral Immune Activation follows Elective Sigmoidoscopy or Circumcision in a Cohort Study of MSM at Risk of HIV Infection. PLoS One 2016 united states
Projected economic evaluation of the national implementation of a hypothetical HIV vaccination program among adolescents in South Africa, 2012. BMC Public Health 2016 england
Pooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials. PLoS One 2016 united states
Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. PLoS Pathog 2016 united states
Power/sample size calculations for assessing correlates of risk in clinical efficacy trials. Stat Med 2016 england
Multiparameter analysis of stimulated human peripheral blood mononuclear cells: A comparison of mass and fluorescence cytometry. Cytometry A 2016 united states
Mark-specific hazard ratio model with missing multivariate marks. Lifetime Data Anal 2016 united states
Feasibility of Identifying a Female Sex Worker Cohort at High Risk of HIV Infection in the Caribbean for HIV Vaccine Efficacy Trials: Longitudinal Results of HVTN 907. J Acquir Immune Defic Syndr 2016 united states
Goodness-of-fit test of the stratified mark-specific proportional hazards model with continuous mark. Comput Stat Data Anal 2016 netherlands
Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083. J Infect Dis 2016 united states
Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial. Ann Intern Med 2016 united states
Approaches to preventative and therapeutic HIV vaccines. Curr Opin Virol 2016 netherlands
Female genital tract inflammation, HIV co-infection and persistent mucosal Human Papillomavirus (HPV) infections. Virology 2016 united states
Adenovirus-based HIV-1 vaccine candidates tested in efficacy trials elicit CD8+ T cells with limited breadth of HIV-1 inhibition. AIDS 2016 england
Engaging Transgender People in NIH-Funded HIV/AIDS Clinical Trials Research. J Acquir Immune Defic Syndr 2016 united states
Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS? PLoS Biol 2016 united states
CXCL13 is a plasma biomarker of germinal center activity. Proc Natl Acad Sci U S A 2016 united states
Increased Steady-State Memory B Cell Subsets Among High-Risk Participants in an HIV Vaccine Trial. AIDS Res Hum Retroviruses 2016 united states
Lower Viral Loads and Slower CD4+ T-Cell Count Decline in MRKAd5 HIV-1 Vaccinees Expressing Disease-Susceptible HLA-B*58:02. J Infect Dis 2016 united states
Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. Curr Opin Virol 2016 netherlands
Statistical methods for down-selection of treatment regimens based on multiple endpoints, with application to HIV vaccine trials. Biostatistics 2016 england
Project Title: Loc: hiv vaccine trials network
Project Number: 5UM1AI068614-11
Project web address: Follow on NIH
 
Title Year
Project Title: Loc: hiv vaccine trials network
Project Number: 5UM1AI068614-11
Project web address: Follow on NIH
 
Title Phase Year